Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vir Biotechnology's ebitda for the twelve months ending Sep 30, 2026 was -$200.12M. For fiscal 2025 it was -$467.65M. The highest annual figure on record is $839.85M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$467.65M | – |
| FY2024 | Dec 31, 2024 | -$572.61M | – |
| FY2023 | Dec 31, 2023 | -$664.85M | -179.2% |
| FY2022 | Dec 31, 2022 | $839.85M | +97.1% |
| FY2021 | Dec 31, 2021 | $426.03M | – |
| FY2020 | Dec 31, 2020 | -$292.58M | – |
| FY2019 | Dec 31, 2019 | -$174.69M | – |
| FY2018 | Dec 31, 2018 | -$117.07M | – |
| FY2017 | Dec 31, 2017 | -$81.24M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$101.89M | – |
| Q2 FY2026 | Jun 30, 2026 | $76.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$129.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$45.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$170.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$115.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$136.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$114.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$228.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$154.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$75.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$134.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$182.23M | -192.7% |
| Q2 FY2023 | Jun 30, 2023 | -$210.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$137.73M | -113.6% |
| Q4 FY2022 | Dec 31, 2022 | -$148.15M | -125.8% |
| Q3 FY2022 | Sep 30, 2022 | $196.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$223.72M | -459.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.02B | – |
| Q4 FY2021 | Dec 31, 2021 | $573.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$51.99M | – |
| Q2 FY2021 | Jun 30, 2021 | $62.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$157.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$107.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$86.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$70.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$62.90M | – |
| Q3 FY2019 | Sep 30, 2019 | -$46.78M | – |
| Q2 FY2019 | Jun 30, 2019 | -$34.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.06M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$33.95M | – |
See a number that looks wrong?